WHO Endorses Weight-Loss Drugs for Obesity, Urges Shift in Global Mindset on Treatment

The World Health Organization (WHO) has taken a landmark step by endorsing the use of weight-loss drugs for obesity management in adults, marking a significant shift in the global approach to this chronic condition. According to draft guidance released by WHO experts, weight-loss medications, particularly the class known as GLP-1 receptor agonists, will be recommended for adults with a body mass index (BMI) of 30 or higher. This guidance comes amid the increasing global prevalence of obesity, affecting over 1 billion people worldwide and contributing substantially to avoidable mortality.

The recommendation, currently open for public consultation until late September 2025, emphasizes managing obesity as a serious chronic disease that requires comprehensive treatment beyond lifestyle changes alone. The drugs highlighted include well-known medications developed by pharmaceutical giants Novo Nordisk and Eli Lilly, such as semaglutide (marketed as Wegovy) and tirzepatide (sold as Mounjaro or Zepbound). These medications mimic the hormone GLP-1, which regulates appetite and slows digestion, promoting feelings of fullness and enabling significant weight loss typically ranging between 15% to 20% of body weight in clinical trials.

This endorsement by WHO represents the first time the agency has formally recognized these drugs as integral to obesity management, potentially setting a global standard for care. The decision accompanies WHO’s inclusion of these medications on its 2025 Model List of Essential Medicines, underscoring their importance in addressing the health burden of obesity globally. However, the high cost of these treatments, often exceeding $1,000 per month in high-income countries, remains a major concern, limiting access particularly in low- and middle-income nations where obesity rates are rising steadily. The WHO calls for efforts to improve affordability and equitable access, including the production of affordable generics.

Experts welcome the WHO guidance as a necessary evolution in public health policy. Dr. Jane Smith, an endocrinologist unaffiliated with the WHO review panel, notes, “Recognizing obesity as a chronic disease and utilizing effective pharmacologic treatments helps shift the narrative away from stigma and individual blame towards evidence-based comprehensive care.” However, she cautions that these drugs should complement, not replace, lifestyle interventions including diet and physical activity.

Further developments in weight-loss medications are underway, with pharmaceutical companies advancing newer agents targeting multiple hormonal pathways. Early trial data suggest promising results, including even greater weight loss and improved metabolic health outcomes. Nonetheless, long-term effects, safety profiles, and strategies for sustained weight management after drug cessation remain areas of active research.

Behavioral and psychological factors also play a crucial role in obesity management. Studies indicate that mindset shifts emphasizing health benefits can influence portion control and eating behavior, complementing pharmacotherapy in a holistic treatment approach.

For the public, the WHO’s endorsement signals that medications for obesity are now recognized as a valid and valuable treatment option for those meeting clinical criteria. Patients are advised to consult healthcare professionals to discuss suitable treatments in the context of individual health needs and to remain aware of potential side effects and the importance of ongoing medical supervision.

Medical Disclaimer:

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References